Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 | 2016-10-31 | 2015-10-31 | 2014-10-31 | 2013-10-31 | 2012-10-31 | 2011-10-31 | 2010-10-31 | 2009-10-31 | 2008-10-31 | 2007-10-31 | 2006-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $7.2B | $6.9B | $6.5B | $6.8B | $6.8B | $6.3B | $5.3B | $5.2B | $4.9B | $4.5B | $4.2B | $4.0B | $4.0B | $3.9B | $6.9B | $6.6B | $5.4B | $4.5B | $5.8B | $5.4B | $5.0B |
| Bruttoergebnis | $3.8B | $3.6B | $3.5B | $3.5B | $3.7B | $3.4B | $2.8B | $2.8B | $2.7B | $2.4B | $2.2B | $2.0B | $2.0B | $1.9B | $3.6B | $3.5B | $2.9B | $2.3B | $3.2B | $3.0B | $2.7B |
| Bruttomarge % | 53.0% | 52.4% | 54.3% | 50.7% | 54.4% | 53.9% | 53.1% | 54.3% | 54.7% | 53.9% | 52.3% | 50.5% | 48.8% | 49.0% | 52.5% | 53.3% | 53.8% | 51.1% | 55.4% | 54.8% | 53.4% |
| Betriebsergebnis (EBIT) | $1.6B | $1.5B | $1.5B | $1.4B | $1.6B | $1.3B | $846M | $941M | $904M | $841M | $615M | $522M | $419M | $386M | $1.1B | $1.1B | $566M | $47M | $795M | $584M | $464M |
| Operative Marge % | 21.5% | 21.3% | 22.9% | 19.8% | 23.6% | 21.3% | 15.8% | 18.2% | 18.4% | 18.8% | 14.6% | 12.9% | 10.3% | 9.9% | 16.3% | 16.2% | 10.4% | 1.1% | 13.8% | 10.8% | 9.3% |
| Jahresüberschuss | $1.4B | $1.3B | $1.3B | $1.2B | $1.3B | $1.2B | $719M | $1.1B | $316M | $684M | $460M | $401M | $549M | $724M | $1.2B | $1.0B | $684M | ($31M) | $693M | $638M | $3.3B |
| Nettomarge % | 19.6% | 18.8% | 19.8% | 18.1% | 18.3% | 19.1% | 13.5% | 20.7% | 6.4% | 15.3% | 10.9% | 9.9% | 13.6% | 18.6% | 16.8% | 15.3% | 12.6% | -0.7% | 12.0% | 11.8% | 66.5% |
| EBITDA | $2.0B | $1.8B | $1.9B | $1.7B | $1.9B | $1.8B | $1.2B | $1.2B | $1.2B | $1.1B | $863M | $799M | $723M | $758M | $1.4B | $1.4B | $1.0B | $257M | $1.1B | $775M | $634M |
| Ergebnis je Aktie (EPS) | $5.81 | $5.58 | $5.29 | $5.45 | $5.21 | $4.34 | $3.28 | $3.12 | $2.79 | $2.37 | $1.98 | $1.73 | $3.05 | $2.89 | $3.12 | $2.95 | $2.00 | $0.80 | $1.95 | $1.55 | $1.54 |
| Ausstehende Aktien (Mio.) | 284M | 284M | 291M | 296M | 300M | 307M | 312M | 318M | 325M | 326M | 329M | 335M | 338M | 345M | 353M | 355M | 353M | 346M | 371M | 406M | 441M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für A. /companies/us/A
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms